Bayes Syndrome and Myocardial Fibrosis: Mechanistic Links and Clinical Implications
Reviews in Cardiovascular Medicine · 26.06.2026 · 27 (6)
DOI: 10.31083/rcm47928 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Reviews in Cardiovascular Medicine, online erschienen am 26.06.2026. Verfasst von Faxue Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Lanzhou University Second Hospital, 730030 Lanzhou, Gansu, China. Die Arbeit nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Special Fund for Lanzhou University Medical Advancement Project.
Abstract (Originalsprache)
Bayes syndrome is characterized by advanced interatrial block (A-IAB), which is associated with atrial fibrillation (AF) and ischemic stroke, and has gained widespread attention in recent years. Myocardial fibrosis, particularly atrial fibrosis, is a crucial substrate for the onset of AF and for atrial electricomechanical dysfunction. Growing evidence indicates a bidirectional relationship between Bayes syndrome and myocardial fibrosis. Myocardial fibrosis leads to delayed atrial conduction and the development of interatrial block (IAB), whereas IAB may exacerbate fibrosis through electrophysiological and hemodynamic changes. Several clinical studies have demonstrated that Bayes syndrome independently predicts the occurrence and recurrence of AF, ischemic stroke, and mortality. Imaging modalities, including late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) and echocardiography, enable noninvasive assessment of myocardial fibrotic burden and atrial structural and functional remodeling. Integrating electrocardiographic markers with imaging phenotypes may improve risk stratification, rhythm-monitoring strategies, and clinical decision-making. However, current evidence remains limited in terms of mechanistic elucidation and prospective clinical validation. This review synthesizes mechanistic and imaging evidence linking Bayes syndrome with fibrosis, discusses the clinical implications, and highlights potential targets for anti-fibrotic strategies and stroke prevention. This review also outlines key knowledge gaps and priorities for future longitudinal studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Lanzhou University Second Hospital, 730030 Lanzhou, Gansu, China.
- Department of Cardiology, The First School of Clinical Medicine, Lanzhou University, 730013 Lanzhou, Gansu, China.
- Department of Neurology, The Second People's Hospital of Baiyin City, 730910 Baiyin, Gansu, China.
ORCID-Profile: Maomao Zhao
Förderung
- Special Fund for Lanzhou University Medical Advancement Project
Zitieren
APA
Li, F., Zhao, M., Yu, R., Guo, X., Ji, W., Zhang, W., & Wu, Q. (2026). Bayes Syndrome and Myocardial Fibrosis: Mechanistic Links and Clinical Implications. Reviews in Cardiovascular Medicine, 27(6). https://doi.org/10.31083/rcm47928
Vancouver
Li F, Zhao M, Yu R, Guo X, Ji W, Zhang W, et al. Bayes Syndrome and Myocardial Fibrosis: Mechanistic Links and Clinical Implications. Reviews in Cardiovascular Medicine. 2026;27(6). doi:10.31083/rcm47928
BibTeX
@article{Li2026,
author = {Li, Faxue and Zhao, Maomao and Yu, Rongbo and Guo, Xuan and Ji, Wenyi and Zhang, Wenliang and Wu, Qiang},
title = {Bayes Syndrome and Myocardial Fibrosis: Mechanistic Links and Clinical Implications},
journal = {Reviews in Cardiovascular Medicine},
year = {2026},
volume = {27},
number = {6},
doi = {10.31083/rcm47928}
}
EUVIMED